TrialThe Journal of clinical endocrinology and metabolism2025

Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12.

Bente Langdahl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.